Tags

Type your tag names separated by a space and hit enter

Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide.
Am J Ophthalmol 2005; 139(6):1073-9AJ

Abstract

PURPOSE

To report on visual outcome after intravitreal injection of triamcinolone acetonide for exudative age-related macular degeneration.

DESIGN

Interventional comparative non-randomized clinical trial.

PATIENTS

Twenty consecutive patients with bilateral exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularisation.

INTERVENTIONS

Unilateral intravitreal injection of about 20 mg triamcinolone acetonide into the eye (study group) more severely affected or showing more pronounced progression of the disease. Mean follow-up was 13.5 +/- 4.1 months.

MAIN OUTCOME MEASURES

Visual acuity.

RESULTS

In the study group, visual acuity increased significantly (P < 0.001) from 0.96 +/- 0.32 logMar to a mean maximum of 0.76 +/- 0.30 logMar during follow-up. An increase in best visual acuity during follow-up was found in 18 (90%) eyes. In 11 (55%) eyes and 7 (35%) eyes, respectively, best visual acuity increased by at least two Snellen lines and three Snellen lines, respectively. In the control group, visual acuity at baseline and the highest visual acuity measurements during follow-up did not vary significantly (P = 0.90). Comparing study group and control group, visual acuity gain was significantly (P = 0.003) higher in the study group. Correspondingly, the number of eyes with an increase in visual acuity (P = 0.002) and with an increase in visual acuity higher > or = 3 lines compared to a loss of > or = 3 lines was significantly (P = 0.027) higher in the study group.

CONCLUSIONS

Intravitreal triamcinolone acetonide may temporarily increase visual acuity in eyes with exudative age-related macular degeneration.

Authors+Show Affiliations

Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, University Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. Jost.Jonas@augen.ma.uni-heidelberg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

15953439

Citation

Jonas, Jost B., et al. "Intereye Difference in Exudative Age-related Macular Degeneration With Minimally Classic or Occult Subfoveal Neovascularization After Unilateral Intravitreal Injection of Triamcinolone Acetonide." American Journal of Ophthalmology, vol. 139, no. 6, 2005, pp. 1073-9.
Jonas JB, Spandau UH, Harder B, et al. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 2005;139(6):1073-9.
Jonas, J. B., Spandau, U. H., Harder, B., Vossmerbaeumer, U., & Kamppeter, B. A. (2005). Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. American Journal of Ophthalmology, 139(6), pp. 1073-9.
Jonas JB, et al. Intereye Difference in Exudative Age-related Macular Degeneration With Minimally Classic or Occult Subfoveal Neovascularization After Unilateral Intravitreal Injection of Triamcinolone Acetonide. Am J Ophthalmol. 2005;139(6):1073-9. PubMed PMID: 15953439.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. AU - Jonas,Jost B, AU - Spandau,Ulrich H, AU - Harder,Björn, AU - Vossmerbaeumer,Urs, AU - Kamppeter,Bernd A, PY - 2004/08/30/received PY - 2005/01/24/revised PY - 2005/01/24/accepted PY - 2005/6/15/pubmed PY - 2005/7/29/medline PY - 2005/6/15/entrez SP - 1073 EP - 9 JF - American journal of ophthalmology JO - Am. J. Ophthalmol. VL - 139 IS - 6 N2 - PURPOSE: To report on visual outcome after intravitreal injection of triamcinolone acetonide for exudative age-related macular degeneration. DESIGN: Interventional comparative non-randomized clinical trial. PATIENTS: Twenty consecutive patients with bilateral exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularisation. INTERVENTIONS: Unilateral intravitreal injection of about 20 mg triamcinolone acetonide into the eye (study group) more severely affected or showing more pronounced progression of the disease. Mean follow-up was 13.5 +/- 4.1 months. MAIN OUTCOME MEASURES: Visual acuity. RESULTS: In the study group, visual acuity increased significantly (P < 0.001) from 0.96 +/- 0.32 logMar to a mean maximum of 0.76 +/- 0.30 logMar during follow-up. An increase in best visual acuity during follow-up was found in 18 (90%) eyes. In 11 (55%) eyes and 7 (35%) eyes, respectively, best visual acuity increased by at least two Snellen lines and three Snellen lines, respectively. In the control group, visual acuity at baseline and the highest visual acuity measurements during follow-up did not vary significantly (P = 0.90). Comparing study group and control group, visual acuity gain was significantly (P = 0.003) higher in the study group. Correspondingly, the number of eyes with an increase in visual acuity (P = 0.002) and with an increase in visual acuity higher > or = 3 lines compared to a loss of > or = 3 lines was significantly (P = 0.027) higher in the study group. CONCLUSIONS: Intravitreal triamcinolone acetonide may temporarily increase visual acuity in eyes with exudative age-related macular degeneration. SN - 0002-9394 UR - https://www.unboundmedicine.com/medline/citation/15953439/Intereye_difference_in_exudative_age_related_macular_degeneration_with_minimally_classic_or_occult_subfoveal_neovascularization_after_unilateral_intravitreal_injection_of_triamcinolone_acetonide_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9394(05)00101-7 DB - PRIME DP - Unbound Medicine ER -